MA40580A - Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques - Google Patents

Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Info

Publication number
MA40580A
MA40580A MA040580A MA40580A MA40580A MA 40580 A MA40580 A MA 40580A MA 040580 A MA040580 A MA 040580A MA 40580 A MA40580 A MA 40580A MA 40580 A MA40580 A MA 40580A
Authority
MA
Morocco
Prior art keywords
integrin
antagonists
beta
alpha
treatment
Prior art date
Application number
MA040580A
Other languages
English (en)
Other versions
MA40580B1 (fr
Inventor
Niall Andrew Anderson
Matthew Howard James Campbell-Crawford
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40580A publication Critical patent/MA40580A/fr
Publication of MA40580B1 publication Critical patent/MA40580B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de formule (i), ce dernier étant un acide 4-(3-fluoro-3-(2-(5, 6, 7, 8-tétrahydro-l, 8-naphthyridin-2-yl) éthyl) pyrrolidin-l-yl)-3-(3-(2-méthoxyéthoxy) phényl) butanoïque, ou un sel de ce dernier.
MA40580A 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques MA40580B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
EP15767475.5A EP3197892B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
PCT/EP2015/071776 WO2016046225A1 (fr) 2014-09-26 2015-09-22 Nouveaux composés

Publications (2)

Publication Number Publication Date
MA40580A true MA40580A (fr) 2017-08-02
MA40580B1 MA40580B1 (fr) 2018-09-28

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40580A MA40580B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Country Status (37)

Country Link
US (3) US9956209B2 (fr)
EP (2) EP3197892B1 (fr)
JP (1) JP6611799B2 (fr)
KR (1) KR101998000B1 (fr)
CN (1) CN107074848B (fr)
AR (1) AR101994A1 (fr)
AU (1) AU2015320858B2 (fr)
BR (1) BR112017006251A2 (fr)
CA (1) CA2962315A1 (fr)
CL (1) CL2017000705A1 (fr)
CO (1) CO2017002714A2 (fr)
CR (1) CR20170112A (fr)
CY (1) CY1121071T1 (fr)
DK (1) DK3197892T3 (fr)
DO (1) DOP2017000081A (fr)
EA (1) EA031481B1 (fr)
ES (1) ES2690748T3 (fr)
GB (1) GB201417002D0 (fr)
HR (1) HRP20181796T1 (fr)
HU (1) HUE041827T2 (fr)
IL (1) IL250592A0 (fr)
JO (1) JO3413B1 (fr)
LT (1) LT3197892T (fr)
MA (1) MA40580B1 (fr)
MX (1) MX2017003948A (fr)
PE (1) PE20170502A1 (fr)
PH (1) PH12017500361B1 (fr)
PL (1) PL3197892T3 (fr)
PT (1) PT3197892T (fr)
RS (1) RS58000B1 (fr)
SG (1) SG11201701183YA (fr)
SI (1) SI3197892T1 (fr)
SM (1) SMT201800513T1 (fr)
TW (1) TW201629056A (fr)
UA (1) UA119181C2 (fr)
UY (1) UY36314A (fr)
WO (1) WO2016046225A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
KR102506327B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체
SI3538528T1 (sl) 2016-11-08 2021-03-31 Bristol-Myers Squibb Company Pirol amidi kot alfa v integrin inhibitorji
AU2017359025A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors
WO2018089353A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
MX2019005234A (es) 2016-11-08 2019-08-12 Squibb Bristol Myers Co Amidas y aminas de azol como inhibidores de integrina alfa v.
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
ES2904645T3 (es) 2017-11-07 2022-04-05 Bristol Myers Squibb Co Derivados de pirrolopirazina como inhibidores de integrina alfa v
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
WO2020047207A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
EP4086254B1 (fr) * 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Inhibiteurs d'intégrine
FI3844162T3 (fi) 2018-08-29 2025-03-27 Morphic Therapeutic Inc Alfa v beeta6 -integriinin estäjiä
WO2020047208A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241192T3 (es) 1997-12-17 2005-10-16 MERCK & CO., INC. (A NEW JERSEY CORP.) Antagonistas del receptor de integrina.
WO1999030709A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
PT1187592E (pt) 1999-06-02 2007-10-19 Merck & Co Inc Antagonistas dos receptores de integrina alfa v
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
EP1229910A4 (fr) * 1999-10-04 2003-10-01 Merck & Co Inc Antagonistes des recepteurs d'integrine
CZ20021508A3 (cs) 1999-11-08 2002-10-16 Merck & Co., Inc. Způsob výroby imidazolidinonových derivátů
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
DE60126496T2 (de) 2000-07-26 2007-11-15 Merck & Co., Inc. Alpha v integrin-rezeptor-antagonisten
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
JP2004517853A (ja) 2001-01-03 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド 歯周病の治療方法及び治療用組成物
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
RS53151B (sr) 2007-03-23 2014-06-30 Amgen Inc. 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k)
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (fr) 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
KR101998000B1 (ko) 2019-07-08
AU2015320858A1 (en) 2017-03-09
SMT201800513T1 (it) 2018-11-09
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
HRP20181796T1 (hr) 2018-12-28
UA119181C2 (uk) 2019-05-10
MA40580B1 (fr) 2018-09-28
CL2017000705A1 (es) 2017-11-03
US20190275016A1 (en) 2019-09-12
MX2017003948A (es) 2017-06-26
EA031481B1 (ru) 2019-01-31
JP6611799B2 (ja) 2019-11-27
US10342783B2 (en) 2019-07-09
TW201629056A (zh) 2016-08-16
CR20170112A (es) 2017-05-26
HUE041827T2 (hu) 2019-05-28
CA2962315A1 (fr) 2016-03-31
PE20170502A1 (es) 2017-04-27
RS58000B1 (sr) 2019-01-31
JP2017528507A (ja) 2017-09-28
PL3197892T3 (pl) 2019-05-31
UY36314A (es) 2016-04-29
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
DK3197892T3 (en) 2018-11-26
JO3413B1 (ar) 2019-10-20
KR20170055489A (ko) 2017-05-19
CN107074848B (zh) 2019-11-01
AR101994A1 (es) 2017-01-25
US20170290817A1 (en) 2017-10-12
PH12017500361A1 (en) 2017-07-17
EA201790715A1 (ru) 2017-07-31
US9956209B2 (en) 2018-05-01
CY1121071T1 (el) 2019-12-11
PH12017500361B1 (en) 2017-07-17
EP3428167A1 (fr) 2019-01-16
ES2690748T3 (es) 2018-11-22
EP3197892B1 (fr) 2018-09-05
DOP2017000081A (es) 2017-04-30
CO2017002714A2 (es) 2017-06-30
PT3197892T (pt) 2018-12-12
BR112017006251A2 (pt) 2017-12-12
WO2016046225A1 (fr) 2016-03-31
AU2015320858B2 (en) 2018-10-18
SG11201701183YA (en) 2017-04-27
CN107074848A (zh) 2017-08-18
EP3197892A1 (fr) 2017-08-02
US20180271845A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
MA40580A (fr) Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MA35725B1 (fr) Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
PH12016501440A1 (en) Novel heterocyclic compounds
EP3952865A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MX378717B (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
MA40302B1 (fr) Dérivés de carbazole
WO2015100092A3 (fr) Analogues 7-bêta d'orvinols
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EP3854220A4 (fr) Additif alimentaire pour bétail comprenant du n-acétyl-l-tryptophane en tant que principe actif
EP4036095A4 (fr) Composés de pyrazolopyridine utiles en tant qu'inhibiteurs sélectifs de la btk kinase
MA41311B1 (fr) Peptides antagonistes du cgrp
EA033085B1 (ru) Производные 2-(1-гетероарилпиперазин-4-ил)метил-1,4- бензодиоксана в качестве альфа2c-антагонистов
EA201600507A2 (ru) Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
MA42602B1 (fr) Antagonistes du recepteur cgrp